Aeterna Zentaris (NASDAQ:AEZS) Receives New Coverage from Analysts at

Research analysts at started coverage on shares of Aeterna Zentaris (NASDAQ:AEZSGet Rating) (TSE:AEZ) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Price Performance

Shares of Aeterna Zentaris stock opened at $2.72 on Friday. The company has a market capitalization of $13.19 million, a PE ratio of -1.06 and a beta of 1.43. Aeterna Zentaris has a 1-year low of $2.54 and a 1-year high of $9.75. The business has a 50-day moving average of $3.47 and a 200-day moving average of $3.70.

About Aeterna Zentaris

(Get Rating)

Æterna Zentaris, Inc operates as a specialty biopharmaceutical company, which engages in the development of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Recommended Stories

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with's FREE daily email newsletter.